Role of GnRH Agonists and Antagonists in Breast Cancer Treatment
Clinical Applications
- The American Society of Clinical Oncology recommends GnRH agonists for ovarian suppression in premenopausal women with hormone receptor-positive breast cancer, which can be combined with tamoxifen or aromatase inhibitors to enhance efficacy in high-risk patients 1, 2
- The treatment duration is typically 5 years, with monthly administration being the standard protocol, and is particularly beneficial in patients who received adjuvant chemotherapy 1, 4
- GnRH agonists may protect follicles from chemotherapy-induced damage by suppressing gonadotropin levels and reducing utero-ovarian perfusion, with meta-analyses showing reduced risk of premature ovarian insufficiency in young breast cancer patients 5
Monitoring and Administration
- GnRH agonist therapy is not universally guaranteed to achieve complete ovarian suppression, and some patients may have persistent elevations in estradiol levels despite amenorrhea 3, 4
- For patients receiving aromatase inhibitors with ovarian suppression, monitoring estradiol levels using high-sensitivity assays is important, and GnRH agonists are typically administered monthly, though every 3-month administration can be considered as a reasonable alternative 2, 4
Side Effects and Management
- Common side effects of GnRH agonists include menopausal symptoms, and accelerated bone loss occurs with prolonged use, approximately 1% of bone mass lost per month 3, 4, 6
- Add-back therapy with low-dose estrogen and progestin is essential for long-term management to mitigate hypoestrogenic side effects, and for patients with intolerable symptoms, clinicians should have a low threshold for reevaluating the benefits versus risks 4, 6